Positron Emission Tomography Using [¹⁸F]Fluorodeoxyglucose for Monitoring Primary Chemotherapy in Breast Cancer

Abstract

This study demonstrates that in patients with advanced breast cancer undergoing primary chemotherapy, FDG-PET differentiates responders from nonresponders early in the course of therapy. This may help improve patient management by avoiding ineffective chemotherapy and supporting the decision to continue dose-intensive preoperative chemotherapy in responding patients.